WallStSmart

Eli Lilly and Company (LLY)vsPark Dental Partners, Inc. Common Stock (PARK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 29015% more annual revenue ($72.25B vs $248.15M). LLY leads profitability with a 35.0% profit margin vs -0.9%. LLY earns a higher WallStSmart Score of 78/100 (B+).

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

PARK

Hold

37

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 4/9Altman Z: 1.34

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$948.95B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

PARK2 strengths · Avg: 9.0/10
EPS GrowthGrowth
526.0%10/10

Earnings expanding 526.0% YoY

Free Cash FlowQuality
$2.72B8/10

Generating 2.7B in free cash flow

Areas to Watch

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.393/10

Elevated debt levels

Price/BookValuation
32.4x2/10

Trading at 32.4x book value

PARK4 concerns · Avg: 2.0/10
Market CapQuality
$85.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-18.6%2/10

ROE of -18.6% — below average capital efficiency

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Profit MarginProfitability
-0.9%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bull Case : PARK

The strongest argument for PARK centers on EPS Growth, Free Cash Flow.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.

Bear Case : PARK

The primary concerns for PARK are Market Cap, Return on Equity, Altman Z-Score. Debt-to-equity of 2.35 is elevated, increasing financial risk.

Key Dynamics to Monitor

LLY profiles as a growth stock while PARK is a turnaround play — different risk/reward profiles.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (78/100 vs 37/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Park Dental Partners, Inc. Common Stock

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Park Dental Partners, Inc. is a dental resource organization that offers business support services to dentists throughout Minnesota and Wisconsin. The company is headquartered in Roseville, Minnesota.

Visit Website →

Want to dig deeper into these stocks?